Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response

Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ErbB2 Receptor Tyrosine Kinase 4 (ERBB4) is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM....

Descripción completa

Detalles Bibliográficos
Autores principales: Donoghue, Jacqueline F., Kerr, Lauren T., Alexander, Naomi W., Greenall, Sameer A., Longano, Anthony B., Gottardo, Nicholas G., Wang, Rong, Tabar, Viviane, Adams, Timothy E., Mischel, Paul S., Johns, Terrance G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116191/
https://www.ncbi.nlm.nih.gov/pubmed/30044378
http://dx.doi.org/10.3390/cancers10080243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116191/
https://www.ncbi.nlm.nih.gov/pubmed/30044378
http://dx.doi.org/10.3390/cancers10080243

Ejemplares similares